First National Bank Of Mount Dora Trust Investment Services Cut Its Amphenol New (APH) Holding; Cannabis Science (CBIS) Sentiment Is NaN

Cannabis Science Inc (CBIS) investors sentiment NaN in Q3 2017. It’s in 2017Q2. The ratio [12345], as 1 investment professionals started new and increased holdings, while 2 sold and trimmed positions in Cannabis Science Inc. The investment professionals in our database reported: 304,780 shares, down from 359,180 shares in 2017Q2. Also, the number of investment professionals holding Cannabis Science Inc in top ten holdings was flat from 0 to 0 for the same number . Sold All: 2 Reduced: 0 Increased: 1 New Position: 0.

First National Bank Of Mount Dora Trust Investment Services decreased Amphenol Corp New (APH) stake by 15.32% reported in 2017Q3 SEC filing. First National Bank Of Mount Dora Trust Investment Services sold 7,100 shares as Amphenol Corp New (APH)’s stock rose 4.95%. The First National Bank Of Mount Dora Trust Investment Services holds 39,235 shares with $3.32 million value, down from 46,335 last quarter. Amphenol Corp New now has $26.81 billion valuation. The stock decreased 0.90% or $0.8 during the last trading session, reaching $87.8. About 849,164 shares traded. Amphenol Corporation (NYSE:APH) has risen 31.78% since December 31, 2016 and is uptrending. It has outperformed by 15.08% the S&P500.

Among 11 analysts covering Amphenol (NYSE:APH), 5 have Buy rating, 0 Sell and 6 Hold. Therefore 45% are positive. Amphenol had 39 analyst reports since July 23, 2015 according to SRatingsIntel. The firm earned “Hold” rating on Thursday, April 27 by Stifel Nicolaus. The stock has “Buy” rating by Cowen & Co on Friday, September 15. The stock of Amphenol Corporation (NYSE:APH) earned “Buy” rating by Deutsche Bank on Thursday, October 5. Deutsche Bank maintained it with “Buy” rating and $96 target in Thursday, October 26 report. As per Thursday, July 23, the company rating was maintained by RBC Capital Markets. RBC Capital Markets maintained Amphenol Corporation (NYSE:APH) rating on Monday, January 18. RBC Capital Markets has “Top Pick” rating and $55 target. RBC Capital Markets maintained Amphenol Corporation (NYSE:APH) rating on Thursday, October 22. RBC Capital Markets has “Top Pick” rating and $60 target. The stock of Amphenol Corporation (NYSE:APH) earned “Hold” rating by Zacks on Tuesday, September 1. The firm earned “Top Pick” rating on Friday, January 15 by RBC Capital Markets. The stock has “Top Pick” rating by RBC Capital Markets on Wednesday, November 30.

Investors sentiment increased to 0.95 in 2017 Q3. Its up 0.07, from 0.88 in 2017Q2. It is positive, as 32 investors sold APH shares while 193 reduced holdings. 51 funds opened positions while 162 raised stakes. 292.31 million shares or 0.47% less from 293.69 million shares in 2017Q2 were reported. Mackenzie Fincl holds 0.66% or 1.44M shares. 3.78M are held by Northern Trust. Calamos Advsr Lc stated it has 60,288 shares. Rmb Ltd Liability accumulated 11,737 shares. Spectrum Mgmt Gru holds 0.01% or 450 shares. Carroll Associates stated it has 0% of its portfolio in Amphenol Corporation (NYSE:APH). Colony Grp Inc Ltd Llc, a Massachusetts-based fund reported 28,099 shares. Alps Inc stated it has 7,757 shares. Massachusetts-based Fmr Ltd Com has invested 0.4% in Amphenol Corporation (NYSE:APH). Copeland Cap Mngmt Ltd Liability Company holds 0.14% or 24,014 shares. Carderock Mngmt Inc accumulated 74,757 shares. The Massachusetts-based Frontier Capital Ltd has invested 0.46% in Amphenol Corporation (NYSE:APH). Raymond James Serv Inc has invested 0.04% of its portfolio in Amphenol Corporation (NYSE:APH). State Board Of Administration Of Florida Retirement Systems accumulated 440,360 shares or 0.1% of the stock. Virginia Retirement Et Al accumulated 0.16% or 156,700 shares.

Analysts await Amphenol Corporation (NYSE:APH) to report earnings on January, 24. They expect $0.81 earnings per share, up 8.00% or $0.06 from last year’s $0.75 per share. APH’s profit will be $247.33 million for 27.10 P/E if the $0.81 EPS becomes a reality. After $0.88 actual earnings per share reported by Amphenol Corporation for the previous quarter, Wall Street now forecasts -7.95% negative EPS growth.

Since August 3, 2017, it had 0 insider purchases, and 9 insider sales for $60.43 million activity. The insider Gavelle Jean-Luc sold 88,000 shares worth $7.60M. Silverman David M also sold $1.28M worth of Amphenol Corporation (NYSE:APH) shares. The insider WALTER LUC sold $8.58 million. Another trade for 15,000 shares valued at $1.20M was sold by Lampo Craig A. $15.59M worth of stock was sold by NORWITT RICHARD ADAM on Thursday, August 3. Doherty William J sold $4.83 million worth of stock or 61,800 shares.

First National Bank Of Mount Dora Trust Investment Services increased Raytheon Co (NYSE:RTN) stake by 5,320 shares to 17,195 valued at $3.21M in 2017Q3. It also upped Merck & Co Inc (NYSE:MRK) stake by 5,275 shares and now owns 79,350 shares. Valero Energy Corp New (NYSE:VLO) was raised too.

Donaldson Capital Management Llc holds 0% of its portfolio in Cannabis Science, Inc. for 99,780 shares. Frontier Investment Mgmt Co owns 20,000 shares or 0% of their US portfolio. Moreover, Neville Rodie & Shaw Inc has 0% invested in the company for 95,000 shares. The Wisconsin-based North Star Asset Management Inc has invested 0% in the stock. Oxbow Advisors Llc, a Texas-based fund reported 15,000 shares.

Cannabis Science, Inc., together with its subsidiaries, develops, produces, and commercializes phytocannabinoid pharmaceutical products primarily in the United States. The company has market cap of $268.71 million. The firm is developing medicines for autism, blood pressure, cancer, cancer side effects, and other illnesses, as well as for general health maintenance. It currently has negative earnings. The Company’s drugs under development include CS-TATI-1 for newly diagnosed and treatment-experienced patients with drug-resistant HIV strains, as well as those intolerant of available therapies; CS-S/BCC-1 to treat basal and squamous cell carcinomas; and a proprietary cannabis therapy for neurological conditions.